Estadístiques de Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature
Visites totals
| views | |
|---|---|
| Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature | 159 |
Visites totals per mes
| views | |
|---|---|
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 1 |
| August 2025 | 3 |
| September 2025 | 0 |
| October 2025 | 1 |
Visites al fitxer
| views | |
|---|---|
| Grau_erait_comp.pdf | 173 |
| Grau_erait_comp.pdf(legacy) | 56 |
Vistes principals per país
| views | |
|---|---|
| United States | 65 |
| Taiwan | 19 |
| Canada | 14 |
| Italy | 10 |
| Romania | 8 |
| Germany | 7 |
| Spain | 7 |
| India | 4 |
| Belgium | 3 |
| Brazil | 3 |
| South Korea | 2 |
| Turkey | 2 |
| Australia | 1 |
| China | 1 |
| Ecuador | 1 |
| France | 1 |
| Georgia | 1 |
| Ireland | 1 |
| Israel | 1 |
| Iran | 1 |
| Netherlands | 1 |
| Peru | 1 |
| Qatar | 1 |
| Sweden | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Taipei | 19 |
| Courtright | 13 |
| Adjud | 8 |
| Ann Arbor | 8 |
| Sassari | 8 |
| Ashburn | 7 |
| Menlo Park | 7 |
| San Ramon | 5 |
| Barcelona | 4 |
| Boardman | 4 |
| Diadema | 3 |
| Mountain View | 3 |
| San Diego | 3 |
| Cambridge | 2 |
| Fairfield | 2 |
| Falls Church | 2 |
| Orem | 2 |
| Redwood City | 2 |
| Valencia | 2 |
| Acerra | 1 |
| Airoli | 1 |
| Ala | 1 |
| Amstelveen | 1 |
| Durham | 1 |
| Lima | 1 |
| Littleton | 1 |
| Llanera | 1 |
| Nagpur | 1 |
| Quito | 1 |
| Rochester | 1 |
| Sacramento | 1 |
| San Jose | 1 |
| Santa Clara | 1 |
| Shenzhen | 1 |
| Stockholm | 1 |
| Walhalla | 1 |
| Woodbridge | 1 |